Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Gains from Investment Securities (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Gains from Investment Securities data on record, last reported at $1.8 million in Q4 2025.

  • For Q4 2025, Gains from Investment Securities fell 72.7% year-over-year to $1.8 million; the TTM value through Dec 2025 reached $1.7 million, down 63.24%, while the annual FY2025 figure was $1.7 million, 63.24% down from the prior year.
  • Gains from Investment Securities reached $1.8 million in Q4 2025 per TRDA's latest filing, up from -$36000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $33.0 million in Q1 2022 and bottomed at -$33.0 million in Q2 2022.
  • Average Gains from Investment Securities over 4 years is $1.7 million, with a median of $678000.0 recorded in 2023.
  • Peak YoY movement for Gains from Investment Securities: surged 124.97% in 2024, then crashed 3500.0% in 2025.
  • A 4-year view of Gains from Investment Securities shows it stood at $4.3 million in 2022, then tumbled by 31.7% to $3.0 million in 2023, then soared by 124.97% to $6.7 million in 2024, then plummeted by 72.7% to $1.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $1.8 million in Q4 2025, -$36000.0 in Q3 2025, and -$40000.0 in Q2 2025.